CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENTDevelopment and Co-Commercialization Agreement • May 14th, 2018 • Arcturus Therapeutics Ltd. • Pharmaceutical preparations • New York
This CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT (this “Agreement”) is made as of 1 January 2018 (the “Effective Date”), by and between Arcturus Therapeutics, Inc., a Delaware corporation with offices at 10628 Science Center Drive, Suite 200, San Diego, California 92121, U.S. (“Arcturus”), and CureVac AG, a German stock corporation with offices at Paul-Ehrlich-Strasse 15, 72076 Tuebingen, Germany (“CureVac”). CureVac and Arcturus are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
